Status:
COMPLETED
Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Immunocompromised Host
Organ Transplantation
Eligibility:
All Genders
Up to 100 years
Brief Summary
Background: * Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppressio...
Detailed Description
Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with substantially elevated cancer risk, largely due to the need to maintain long-term immunosu...
Eligibility Criteria
Inclusion
- This study will include as subjects all individuals included in the transplant data set. All U.S. solid organ transplant recipients, candidates for transplant, and living related donors.
- In addition, the study will include all individuals in the U.S. ESRD data set.
Exclusion
Key Trial Info
Start Date :
July 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 22 2020
Estimated Enrollment :
19929901 Patients enrolled
Trial Details
Trial ID
NCT00904579
Start Date
July 1 2006
End Date
April 22 2020
Last Update
April 28 2020
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
California Cancer Registry
Sacramento, California, United States, 95811
2
Colorado Cancer Registry
Denver, Colorado, United States, 12206
3
Connecticut Cancer Registry
Hartford, Connecticut, United States, 06134
4
Georgia Cancer Registry
Atlanta, Georgia, United States, 30303